Studies from U.S. Food and Drug Administration (FDA) Describe New Findings in Prostate Cancer (Fda Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients With Metastatic Castration-resistant Prostate Cancer).
In: Medical Letter on the CDC & FDA, 2024-05-03, S. 1131-1131
serialPeriodical
Zugriff:
The U.S. Food and Drug Administration (FDA) has approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have been treated with certain medications. The recommended dose is 7.4 gigabecquerels (GBq) intravenously every 6 weeks for up to six doses. The approval was based on a clinical trial that showed a statistically significant improvement in overall survival with the treatment. Common side effects include fatigue, dry mouth, nausea, anemia, decreased appetite, and constipation. This information is summarized from a peer-reviewed article in Clinical Cancer Research. [Extracted from the article]
Copyright of Medical Letter on the CDC & FDA is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Studies from U.S. Food and Drug Administration (FDA) Describe New Findings in Prostate Cancer (Fda Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients With Metastatic Castration-resistant Prostate Cancer).
|
---|---|
Zeitschrift: | Medical Letter on the CDC & FDA, 2024-05-03, S. 1131-1131 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1532-4648 (print) |
Sonstiges: |
|